COVID-19-ის ვაქცინა: განსხვავება გადახედვებს შორის
| [შემოწმებული ვერსია] | [შემოწმებული ვერსია] |
შიგთავსი ამოიშალა შიგთავსი დაემატა
ხაზი 183:
|ადენოვირუსული ვექტორული ვაქცინა ([[ChAdOx1]])<wbr /><ref name="NCT04400838" />
|2 დოზა<br />4–12 კვირა<wbr /><ref>{{cite news|last1=Gallagher |first1=James |last2=Triggle |first2=Nick |date=30 December 2020 |title=Covid-19: Oxford-AstraZeneca vaccine approved for use in UK |url=https://www.bbc.com/news/health-55280671 |work=[[BBC News Online]] |access-date=5 March 2020| name-list-style = vanc}}</ref>
|{{ClinicalStudyInfo|align=left|phase=3|participants=30000
|description=Interventional; [[randomized controlled trial|randomized, placebo-controlled study]] for efficacy, safety, and immunogenicity.<ref name="NCT04516746">{{#invoke:Cite web| |title=A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04516746 |website=[[ClinicalTrials.gov]] |id=NCT04383574 |date=12 May 2020 |access-date=26 August 2020 |archive-date=23 August 2020 |url-status=live|archive-url=https://web.archive.org/web/20200823061231/https://clinicaltrials.gov/ct2/show/NCT04516746 }}</ref>
| |||